Evidence map›Paper›PMID 29026839›Full record

ArticleJournal of research in pharmacy practice

Missing the Benefit of Metformin in Acute Myeloid Leukemia: A Problem of Contrast?

Alice C Ceacareanu, George K Nimako, Zachary A P Wintrob

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of research in pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Research Progress on the Use of Metformin in Leukemia Treatment.Current treatment options in oncology · 2024
    Review
  6. Review
  7. Metformin and Cancer, an Ambiguanidous Relationship.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Article
  10. The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia.International journal of molecular sciences · 2019
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Alice C CeacareanuDepartment of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, University of New York at Buffalo, Buffalo, New York, USA.
George K NimakoDepartment of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, University of New York at Buffalo, Buffalo, New York, USA.
Zachary A P WintrobDepartment of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, University of New York at Buffalo, Buffalo, New York, USA.
University at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate whether metformin's cancer-related benefits reported in patients with solid tumors (ST) are also present in acute myeloid leukemia (AML) patients.

methodsBaseline demographic and clinical history for all diabetes mellitus patients newly diagnosed with AML or cancer of the breast, ovary, prostate, gastrointestinal tract, lung, or kidney at Roswell Park Cancer Institute in Buffalo, NY (January 2003-December 2010,

findingsBaseline metformin use provided significant OS and DFS benefit in ST but not in AML (KM: P

conclusionLack of metformin benefit in AML could be due to advanced age at cancer diagnosis. Metformin substitution with insulin before computed tomography scans with contrast - a frequent AML assessment practice - may also explain the lack of subsequent benefit despite taking metformin at baseline. A temporary metformin substitution is recommended by the package insert due to a possible drug interaction with the contrast dye. Our data suggest that metformin substitution was permanent in many patients. Nonetheless, the observed benefit in other malignancies warrants further investigation of metformin use in AML.

Indexed as

Acute myeloid leukemiadisease-free survivalMetforminoverall survivalsolid tumors

Identifiers

PMID29026839
PMCPMC5632934
OpenAlexW2757161247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.